Mehak Trehan, Associate Consultant at Fortis Healthcare, shared a post on X:
“Excellent learning from Naval Daver, on the evolving frontline AML landscape with Mumbai Hematology group!
The real shift is not just ‘intensive vs non-intensive’ anymore : it is biology-directed therapy: FLT3, IDH1/2, NPM1, KMT2A, TP53, RAS, MRD and transplant strategy all shaping the first decision.
Thank you for answering all the questions patiently.”
More posts featuring Naval Daver.
